🇺🇸 FDA

Company profile · Sponsor

Artiva

Artiva Biotherapeutics

ARTV · NYSE biotech SAN DIEGO, CA, USA
Pipeline
8
Drugs
0
Patents
0

Quick answer

Artiva (ARTV) is a biotech company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker ARTV
Exchange NYSE
Company type biotech
Headquarters SAN DIEGO, CA, USA
SEC CIK 0001817241

Pipeline (8)

Search pipeline →

  1. AB-101

    Artiva

    Non Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  2. AB-201

    Artiva

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  3. AFM13

    Artiva

    Relapsed or Refractory Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  4. Allogeneic NK Cells

    Artiva

    Refractory Rheumatoid Arthritis (RA)

    phase 2 small molecule active

    1 trial

  5. CYCLOPHOSPHAMIDE , RITUXIMAB , AB-101, FLUDARABINE

    Artiva

    Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Sjögren’s Disease (SjD)

    phase 2 small molecule active

    1 trial

  6. AB-101

    Artiva

    Rheumatoid Arthritis

    phase 1 small molecule active

    1 trial

  7. AB-101

    Artiva

    Lupus Nephritis - WHO Class III

    phase 1 small molecule active

    1 trial

  8. GCC2005

    Artiva

    Lymphoma, T-Cell

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is Artiva?

Artiva (ARTV) is a biotech company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Artiva sponsor?

We track 8 ClinicalTrials.gov-linked programs for Artiva, including AB-101 and 7 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Artiva company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.